Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Liabilities and Shareholders Equity (2017 - 2025)

Historic Liabilities and Shareholders Equity for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to $661.9 million.

  • Autolus Therapeutics' Liabilities and Shareholders Equity fell 2000.54% to $661.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year decrease of 155.3%. This contributed to the annual value of $782.7 million for FY2024, which is 10851.48% up from last year.
  • Latest data reveals that Autolus Therapeutics reported Liabilities and Shareholders Equity of $661.9 million as of Q3 2025, which was down 2000.54% from $721.0 million recorded in Q2 2025.
  • Autolus Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $901.4 million during Q1 2024, with a 5-year trough of $263.8 million in Q3 2022.
  • Its 5-year average for Liabilities and Shareholders Equity is $526.4 million, with a median of $451.0 million in 2023.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first tumbled by 2343.44% in 2023, then surged by 10851.48% in 2024.
  • Over the past 5 years, Autolus Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $405.6 million in 2021, then grew by 20.89% to $490.3 million in 2022, then decreased by 23.43% to $375.4 million in 2023, then soared by 108.51% to $782.7 million in 2024, then decreased by 15.43% to $661.9 million in 2025.
  • Its last three reported values are $661.9 million in Q3 2025, $721.0 million for Q2 2025, and $746.3 million during Q1 2025.